<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04196023</url>
  </required_header>
  <id_info>
    <org_study_id>100106a</org_study_id>
    <nct_id>NCT04196023</nct_id>
  </id_info>
  <brief_title>Ca:Mg Ratio and Cognitive Function</brief_title>
  <official_title>Ca:Mg Ratio and Cognitive Function in the Personalized Prevention of Colorectal Cancer Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Between 2000 and 2015, mortality due to Alzheimer's disease (AD) increased by 123%. No drugs
      have yet been approved to stop or slow the progression of AD. A delay of five years in the
      expression of AD would reduce the incidence rate by half. Thus, it is critical to develop
      novel prevention strategies to delay the onset of this common disease.

      As an ancillary study conducted within a precision-based randomized trial (R01CA149633; PI,
      Dai &amp; Yu]&quot;), the investigators reduced Ca:Mg ratios to 2.3 through 3-month personalized Mg
      supplementation among those who consumed high Ca:Mg ratio diet, but otherwise in good general
      health. The investigators test the hypothesis that actively reducing the Ca:Mg ratio among
      those aged &gt;65 years who consume high Ca:Mg ratio diets improves cognitive function compared
      to the placebo arm. The investigators further conduct molecular epidemiologic studies to
      understand the molecular mechanisms.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 12, 2012</start_date>
  <completion_date type="Anticipated">December 12, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 12, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cognitive function</measure>
    <time_frame>12 weeks</time_frame>
    <description>Cognitive function was measured by the Montreal Cognitive Assessment (MoCA)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>APOE Cytosine Modifications</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">123</enrollment>
  <condition>Cognitive Function</condition>
  <arm_group>
    <arm_group_label>GG genotype and magnesium treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants who have the GG genotype will be assigned to magnesium glycinate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GG genotype and placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants who have the GG genotype will be assigned to placebo group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GA/AA genotype and magnesium treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants who have the GA/AA genotype will be assigned to magnesium glycinate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GA/AA genotype and Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants who have the GA/AA genotype will be assigned to placebo group</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Magnesium glycinate</intervention_name>
    <description>Oral administration of magnesium glycinate daily for 12 weeks</description>
    <arm_group_label>GA/AA genotype and magnesium treatment</arm_group_label>
    <arm_group_label>GG genotype and magnesium treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral administration of identical-appearing placebo daily for 12 weeks</description>
    <arm_group_label>GA/AA genotype and Placebo</arm_group_label>
    <arm_group_label>GG genotype and placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Participants from our parent study (Personalized Prevention of Colorectal Cancer
             Trial, NCT#01105169, IRB#100106);

          2. Participants who completed the MoCA

        Exclusion Criteria:

        1. Participants did not provide their blood samples in the parent study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 10, 2019</study_first_submitted>
  <study_first_submitted_qc>December 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 12, 2019</study_first_posted>
  <last_update_submitted>December 11, 2019</last_update_submitted>
  <last_update_submitted_qc>December 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Qi Dai</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

